CDK
Gli inibitori delle chinasi ciclina-dipendenti (CDK) sono composti che bloccano l'attività delle CDK, un gruppo di chinasi proteiche che regolano il ciclo cellulare, la trascrizione e altri processi cellulari. Le CDK vengono attivate legandosi alle cicline e la loro attività è cruciale per la progressione delle cellule attraverso le diverse fasi del ciclo cellulare. Inibire le CDK può bloccare la divisione cellulare, portando all'arresto del ciclo cellulare e all'apoptosi, in particolare nelle cellule tumorali in cui le CDK sono spesso disregolate. Gli inibitori delle CDK sono ampiamente utilizzati nella ricerca sul cancro e hanno un potenziale terapeutico nel trattamento di vari tipi di cancro. Presso CymitQuimica, offriamo una selezione completa di inibitori delle CDK di alta qualità per supportare la tua ricerca sul controllo del ciclo cellulare, sul cancro e sullo sviluppo terapeutico.
Trovati 577 prodotti per "CDK".
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
(E/Z)-THZ1 2HCl
CAS:THZ1 2HCl: selective CDK7 allosteric inhibitor, IC50 3.2 nM, hinders cancer cell growth.Formula:C31H30Cl3N7O2Purezza:99.51%Colore e forma:SolidPeso molecolare:638.975BRD6989
CAS:BRD6989, a cortistatin A analog, inhibits CDK8/19, enhances IL-10, and binds CDK8 with a 200 nM IC50.Formula:C16H16N4Purezza:99.43%Colore e forma:SolidPeso molecolare:264.325CDK2-IN-4
CAS:CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A.Formula:C23H18N6O2SPurezza:97.24% - 99.10%Colore e forma:SolidPeso molecolare:442.493XPW1
CAS:XPW1 is a CDK9 inhibitor with antitumor activity, inhibits DNA repair procedures, and can be used for the research of clear cell renal cell carcinoma.Formula:C36H39ClFN7O2Purezza:99.63%Colore e forma:White SolidPeso molecolare:656.19GSK-3 inhibitor 4
CAS:Orally active GSK-3 inhibitor 4 targets GSK-3α/β, CDK2/5 (IC50: 0.45-0.68 μM) and may aid in Alzheimer's research by lowering Tau protein.Formula:C22H15F2N5OPurezza:99.82%Colore e forma:SolidPeso molecolare:403.38Samuraciclib hydrochloride
CAS:Samuraciclib HCl is an oral CDK7 inhibitor (IC50: 41 nM), 45-230x selective over CDK1/2/5/9, inhibiting breast cancer growth (GI50: 0.2-0.3 μM).Formula:C22H31ClN6OPurezza:99.14% - 99.63%Colore e forma:SolidPeso molecolare:430.974Lerociclib dihydrochloride
CAS:Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 2 nM and 1 nM for CDK6/CyclinD3 and CDK4/Formula:C26H36Cl2N8OPurezza:97.4%Colore e forma:SolidPeso molecolare:547.523Ca2+ channel agonist 1
CAS:Ca2+ channel agonist 1 activates N-type Ca2+ channels and inhibits Cdk2 (EC50: 14.23 μM/3.34 μM) for motor nerve issues.Formula:C19H26N6OPurezza:97.71%Colore e forma:SolidPeso molecolare:354.4493CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Formula:C29H28FN5OColore e forma:SolidPeso molecolare:481.56EGFR/CDK2-IN-4
EGFR/CDK2-IN-4 (compound 4c) is a dual inhibitor targeting EGFR and CDK-2, demonstrating IC50 values of 89.6 nM for EGFR and 165.4 nM for CDK-2.Formula:C24H16N6OS2Purezza:98%Colore e forma:SolidPeso molecolare:468.55CDK9 ligand 3
CAS:CDK9ligand 3 is a ligand for CDK9 and can be utilized in the synthesis of PROTAC degraders, specifically PROTAC CDK9degrader-11.Formula:C18H18BrCl2N5O3Colore e forma:SolidPeso molecolare:503.177CDK7-IN-7
CAS:CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formula:C20H20BrF3N6O2Colore e forma:SolidPeso molecolare:513.319SNX7
CAS:SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formula:C15H14N2OPurezza:99.96%Colore e forma:SolidPeso molecolare:238.2845CDK9-IN-25
CDK9-IN-25 (compound 4a), an imidazopyrazine derivative, functions as a CDK9 inhibitor with an IC50 of 0.24 μM.Formula:C15H16FN5Purezza:98%Colore e forma:SolidPeso molecolare:285.32PROTAC CDK9 degrader-11
CAS:PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC CDK9 degrader with a DC50 of 1.09 nM. This compound exhibits cytotoxicity in small cell lung cancer (SCLC) cells, with IC50 values in the nanomolar range. It induces cell cycle arrest at the G0/G1 phase and inhibits cell invasion in DMS114 and DMS53 cells. In addition, PROTAC CDK9 degrader-11 shows antitumor activity in an NCI-H446 xenograft mouse model. (Pink: ligand for target protein CDK9 ligand 3; Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56)Formula:C39H48Cl2N10O5Colore e forma:SolidPeso molecolare:807.768CDK2 degrader 7
CAS:CDK2 degrader7 is an orally active CDK2 degrader with DC50 values of 13 nM in MKN1 cells and 17 nM in TOV21G cells. It induces G1 phase arrest in MKN1 cells and achieves tumor suppression in the HCC1569 (CCNE1 amplified) xenograft model. CDK2 degrader7 is utilized in research on CCNE1 amplification-type cancers.Formula:C39H46F6N8O5SPeso molecolare:852.9IV-361
CAS:IV-361, an orally active and selective CDK7 inhibitor with a Ki value of less than or equal to 50 nM, demonstrates potent anti-cancer activity (US20190256531A1Formula:C23H32FN5O2SiColore e forma:SolidPeso molecolare:457.6164BSJ-04-132
CAS:BSJ-04-132 is a Ribociclib-based PROTAC that selectively induces CDK4 degradation via CRBN recruitment, with no significant degradation of CDK6 or IKZF1/3.Formula:C42H49N11O7Colore e forma:SolidPeso molecolare:819.91CDK7-IN-5
CAS:CDK7-IN-5, a CDK7 inhibitor with an IC 50 value of less than 100 nM, exhibits potent anticancer properties (WO2015154022A1, Compound 104).Formula:C34H45N9O2Colore e forma:SolidPeso molecolare:611.795LO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Colore e forma:Odour Solid
